Union Chimique Belge is a multinational biopharmaceutical company that manufactures medications for epilepsy, Parkinson's, and Crohn's diseases. In 2011, the company generated €3.2 billion in revenue, with 49% from Europe and 33% from North America. Net profit was €513 million. For 2012, the company expects revenue to remain stable at €3.2 billion and net profit to decrease slightly to €196 million, continuing growth of key drugs like Cimzia, Vimpat, Neupro, and Keppra. UCB is financially strong with a worldwide presence and focus on innovation.